Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Lancet Oncol
; 20(12): 1730-1739, 2019 12.
Article
in En
| MEDLINE
| ID: mdl-31727538
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Prostatic Neoplasms, Castration-Resistant
Type of study:
Clinical_trials
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Aged
/
Aged80
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Lancet Oncol
Journal subject:
NEOPLASIAS
Year:
2019
Document type:
Article
Affiliation country:
Canadá
Country of publication:
Reino Unido